Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...
Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...
The medical board examining Imran Khan reported that his unaided vision is 6/24 in the right eye and 6/9 in the left eye. These numbers refer to visual acuity, which measures how clearly a person can ...
First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...
Ray Therapeutics, a clinical-stage biotechnology company developing optogenetic gene therapies for vision restoration, today ...
Shaukat Khanum CMO Dr Aasim Yusuf says Imran Khan’s eye condition is improving after doctors’ briefing, with medical report showing better vision and ongoing treatment.
AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...
The global intraocular lens market is experiencing sustained momentum driven by the increasing prevalence of cataracts, growing adoption of premium ...
Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...
In patients with dry eye disease, Miebo before cataract surgery had no impact on the accuracy of preoperative measurements ...
Cornerstone Eye Associates has become the first practice in Rochester to offer Valeda Light Therapy for the treatment of dry ...
PharmaPack kits will initially be available in California, Mississippi, Arkansas, Connecticut, and Alabama, with plans to expand nationwide in the coming weeks. Prescribers can access PharmaPack ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results